Digestive Surgery
Case Report
Effective Intra-Arterial Chemotherapy for Acinar Cell Carcinoma of the PancreasUkei T.a · Okagawa K.a · Uemura Y.a · Miyauchi K.a · Kaneko T.a · Mizunoya S.a · Monden M.baDepartment of Surgery, Kinki Central Hospital, Mutual Aid Association of Public School Teachers, Hyougo, and bDepartment of Surgery II, Osaka University School of Medicine, Osaka, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: February 12, 1999
Issue release date: 1999
Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0
ISSN: 0253-4886 (Print)
eISSN: 1421-9883 (Online)
For additional information: https://www.karger.com/DSU
Abstract
A 41-year-old man with a huge pancreatic tumor (acinar cell carcinoma) was treated by intra-arterial infusion chemotherapy with 5-fluorouracil (5-FU), mitomycin C (MMC) and cisplatin (CDDP). The tumor was significantly reduced, and he underwent a pancreaticoduodenectomy with complete excision of the tumor. Unfortunately multiple metastatic liver tumors were noted 5 months after resection. These tumors could also be markedly reduced by intra-arterial chemotherapy and the survival period was prolonged to 18 months. He suddenly died of sepsis but not from the pancreatic carcinoma. This case shows that intra-arterial infusion chemotherapy with 5-FU, MMC and CDDP can be an effective regimen for the treatment of acinar cell carcinoma of the pancreas.
Related Articles:
References
- Jie Chen, Baithun SI: Morphological study of 391 cases of exocrine pancreatic tumors with special reference to the classification of exocrine pancreatic carcinoma. J Pathol 1985;146:17–29.
- Carter S, Comis R: The integration of chemotherapy into combine modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975;2:193–214.
- Schein P, Lavin P, Moertel C, et al: Randomized phase II clinical trial of adriamycin, methotrexate and actinomycin D in advanced measurable pancreatic carcinoma. Cancer 1978;42:19–22.
- Zimmermann SE, Smith FP, Schein PS: Chemotherapy of pancreatic carcinoma. Cancer 1981;47:1724–1728.
- Smith FP, Hoth DF, Levin B, et al: 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980;46:2014–2018.
- Yokoyama T, Shimada Y: Chemotherapy for advanced pancreatic carcinoma. Jpn J Cancer Chemother 1992;19:2338–2343.
- Oster M, Gray R, Panasci L, et al: Chemotherapy for advanced pancreatic cancer. Cancer 1986;57:29–33.
- Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycin-C plus fluorouracil. J Clin Oncol 1986;4:1794–1798.
- Rothman H, Cantrell JE Jr, Lokich J, et al: Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. Cancer 1991;68:264–268.
- Gastrointestinal Tumor Study Group: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986;4:1053–1057.
- Kunimura T, Morohoshi T, Sato M, et al: Histological evaluation of intra-arterial infusion and systemic chemotherapy for pancreatic carcinomas. Jpn J Cancer Chemother 1992;19:355–360.
-
Robertson JC, Eeles GH: Syndrome associated with pancreatic acinar cell carcinoma. Br Med J 1970;ii:708–709.
-
Osborne RR: Functioning acinous cell carcinoma of the pancreas accompanied with widespread focal fat necrosis. Arch Intern Med 1950;85:933–943.
Article / Publication Details
Published online: February 12, 1999
Issue release date: 1999
Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0
ISSN: 0253-4886 (Print)
eISSN: 1421-9883 (Online)
For additional information: https://www.karger.com/DSU
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
